Table 1.
Population characteristics and main echocardiographic data at basal and midterm follow up.
| Population baseline characteristics | Total (n = 38) |
|---|---|
| Age | 64 (37–83) |
| Male(%) | 28 (73%) |
| Ischemic etiology(%) | 10 (26%) |
| LBBB (%) | 37 (97%) |
| QRS duration (ms) | 166 ± 24 |
| AF (%) | 9 (23%) |
| NYHA class III-IV(%) | 16 (42%) |
| SBP (mmHg) | 119 ±18 |
| ACE inhibitors/ARBs therapy (%) | 34 (89%) |
| Beta blocker therapy (%) | 32 (84%) |
| MRA therapy (%) | 20 (52%) |
| Loop diuretics (%) | 37 (97%) |
| HF duration (months) | 76 (35–136) |
| ECHOCARDIOGRAPHIC BASELINE (PRE) CHARACTERISTICS | |
| LVEDVI (ml/m2) | 118 (97–164) |
| LVESVI (ml/m2) | 92 (73–127) |
| LVEF (%) | 22 ± 6 |
| MR ≥ 2+ (%) | 27 (71%) |
| POPULATION CHARACTERISTICS AT MIDTERM FOLLOW UP | |
| Time to Echo at follow up (months) | 7.3 (4–10.5) |
| LVEDVI (ml/m2) | 96 (76–124)* |
| LVESVI (ml/m2) | 67 (48–95) # |
| LVEF (%) | 33 ± 11§ |
| NYHA class III-IV(%) | 8 (21%) |
| MR ≥ 2+ (%) | 21 (55%) |
| QRS duration (ms) | 156 ± 23 |
| Ventricular Pacing (%) | 97 ± 3 |
| SR/R/NR/NegR | 17 (45%) /10 (26%) /5 (13%) /6 (16%) |
Values are expressed as the mean ± SD or median with interquartile range, and as a percentage (%).
LVEDVI, left ventricular end-diastolic volume indexed; LVESVI, left ventricular end-systolic volume indexed; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; SBP, systolic blood pressure; GLS, global longitudinal strain;
*
p < 0,0001 with LVEDVI basal; #p < 0,0001 with LVESVI basal, §p < 0,0001 with LVEF basal, SR, Super responders; R, Responders; NR, Non responders; NegR, Negative responders.